Specifically, your app name and icon include references to controlled substances, pills.Īccording to Gustafson, Apple said it would remove Amphetamine from the App Store by January 12th, 2021, if the violation cited was not addressed. Your app appears to promote inappropriate use of controlled substances. Facilitating the sale of marijuana, tobacco, or controlled substances (except for licensed pharmacies) isn’t allowed. Apps that encourage minors to consume any of these substances will be rejected. Gufstason, details the violation notice he received in a GitHub post:ġ.4.3 Apps that encourage consumption of tobacco and vape products, illegal drugs, or excessive amounts of alcohol are not permitted on the App Store. The app is free to download, and has been live with its current name and branding since 2014.Īpple’s review team did not find an issue with the app itself, but rather that its branding was in violation of App Store Review Guidelines the branded app name and pill graphic in the icon were viewed as evocative of controlled substances. This likely raises the question to other developers- can this happen to me, and what can I do? What Happened?Īmphetamine is a MacOS app that keeps your Mac awake as long as the user specifies, based on times or actions. One developer recently saw their app, which had been live in the Mac app store for years, under threat of removal for a guideline they had never been flagged for violating before. However, being approved previously does not necessarily mean the app will be approved forever. Developers may feel they are in the clear after a build is submitted and approved- especially after several releases go live with no significant changes or issues. She exclusively breastfed her infant for 6 months with no evidence of an adverse effect on milk production.App Store Review Guidelines are an ever-changing document from Apple which must be constantly monitored to ensure your app is compliant. The cause of this difference was not determined.Ī mother took amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum. In a retrospective Australian study, mothers who used intravenous amphetamines during pregnancy were less likely to be breastfeeding their newborn infants at discharge than mothers who abused other drugs (27% vs 42%). The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed. The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women. No assessment of milk production was presented. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. These values represented 15%, 7% and 5% of simultaneous maternal serum concentrations. Infant serum concentrations at these times were 3.1, 2 and 1.4 mcg/L, respectively. Infant blood samples were taken just before the mother's morning amphetamine dose at 2, 5 and 9 weeks postpartum. The infant of a mother who was taking amphetamine 35 mg daily for narcolepsy during pregnancy and postpartum was exclusively breastfed for 6 months. The infant's urinary excretion of amphetamine ranged from 0.1 to 0.3% of the mother's urinary excretion. Amphetamine was measured in a 12-hour urine collection in a breastfed infant whose mother was taking racemic amphetamine 5 mg 4 times daily. These values represent a weight-adjusted dosage of 1.9% to 2.1% of the maternal dosage and an absolute infant dosage of 11.1 to 12.4 mcg/kg daily. Breastmilk levels of amphetamine were 74, 82 and 82 mcg/L, respectively. Breastmilk samples were taken just before her morning dose at 2, 5 and 9 weeks postpartum. Milk levels were 118 and 138 mcg/L before the 2 pm doses on days 10 and 42, respectively.Ī woman took 35 mg of amphetamine daily for narcolepsy and exclusively breastfed her infant for 6 months. Trough milk levels of 55 and 68 mcg/L were found before the 10 am dose on days 10 and 42 postpartum, respectively. A nursing woman was taking racemic amphetamine 5 mg orally 4 times daily at 10 am, noon, 2 pm and 4 pm for narcolepsy.
0 Comments
Leave a Reply. |